ERAS-10
/ Erasca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 28, 2023
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
(GlobeNewswire)
- "As such, we are deprioritizing our ERAS-601 clinical trial (FLAGSHP-1) and our preclinical ERAS-5 ULK inhibitor and ERAS-10 protein degrader programs."
Pipeline update • Trial status • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1